Clinical trial
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT06385080 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- April 22, 2024
- Completion date
- July 28, 2033
- Enrollment
- 287 (estimated)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.